HIV/AIDS remains a major public health threat worldwide, with an estimated 39.9 million people living with the disease at the ...

Discover what non-reactive HIV test results really mean and why testing timing, window periods, and retesting are crucial for ...

Yeztugo demonstrated superiority over Truvada in reducing the risk of incident HIV-1 infections. The Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir) for pre-exposure ...

National HIV Testing Day has raised awareness and confront stereotypes about HIV. Learn about HIV testing options and ...

From the first reported case of AIDS to the present, what is the history of HIV-AIDS and are there parallels to the COVID-19 pandemic?

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Learn what a negative HIV test means, why the window period matters, and when you should consider retesting. Essential health ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

"There is now an urgent need for bolder and more realistic approaches to address HIV transmission among IPT students, similar ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

Worldwide, at least seven people have been "cured" of HIV—or at least have had long-term sustained remission. This means that ...